Industry News

Biotechnology Industry News

Roche has taken its obesity…

August 24th, 2026|FierceBiotech|

Roche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage urocortin-2 analog from South Korea’s Hanmi Pharm.

The “knowledge base is going to…

August 23rd, 2026|FierceBiotech|

The “knowledge base is going to start shifting quickly to China,” Rep. Nathaniel Moran, R-Texas, a member of the House Select Committee on China, told Fierce.

Werewolf Therapeutics’ hunt for…

August 21st, 2026|FierceBiotech|

Werewolf Therapeutics’ hunt for strategic alternatives has ended. Ambros Therapeutics has agreed to merge with Werewolf in an all-stock deal and raised $150 million, positioning the biotech to take its lead rare disease drug candidate

Boehringer Ingelheim has suspended…

August 20th, 2026|FierceBiotech|

Boehringer Ingelheim has suspended a phase 1 trial of an investigational small molecule drug while it seeks to understand a “safety event,” although the German pharma isn't shedding light on the nature of the incident

Joshua Pinto, Ph.D., has been…

August 20th, 2026|FierceBiotech|

Joshua Pinto, Ph.D., has been appointed chief executive officer of Neumora Therapeutics, a clinical-stage biotech with obesity and neuro assets.

As the dust settles on phase 3…

August 20th, 2026|FierceBiotech|

As the dust settles on phase 3 data that added $45 billion to Moderna’s market cap, analysts have begun to ask a question that could define cancer care in the coming years: Can use of

Pheast Therapeutics may have…

August 20th, 2026|FierceBiotech|

Pheast Therapeutics may have learned the hard way about the risks of competitors getting a glimpse of your heard-earned discoveries, but the immuno-oncology startup is so far sticking to its transparent approach.

TScan has told Fierce that its…

August 19th, 2026|FierceBiotech|

TScan has told Fierce that its pipeline strategy remains unchanged despite Amgen walking away from a Crohn’s disease collaboration that had the potential for a windfall of half a billion dollars.

After three months without a…

August 19th, 2026|FierceBiotech|

After three months without a permanent leader in place, President Donald Trump has named his pick for the new commissioner of the FDA. Heidi Overton, M.D., Ph.D., currently a White House aide, will go before

Tolerance Bio has vaulted into the…

August 19th, 2026|FierceBiotech|

Tolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein in certain thymus-related indications in the Americas and Europe.

Merck & Co. and Moderna’s…

August 18th, 2026|FierceBiotech|

Merck & Co. and Moderna's personalized mRNA cancer vaccine has successfully lengthened recurrence-free survival when paired with Keytruda for patients with high-risk skin cancer. The phase 3 win sets the partners up to potentially seek

Following a phase 3 knee…

August 18th, 2026|FierceBiotech|

Following a phase 3 knee osteoarthritis failure that its CEO acknowledged caused “great disappointment and concern,” Kolon TissueGene is laying off 37 employees at its Maryland headquarters.

Oncology R&D organization…

August 18th, 2026|FierceBiotech|

Oncology R&D organization Sarah Cannon Research Institute (SCRI) announced a collaboration with Merck & Co. to increase patient access to oncology trials at community-based sites in the U.S.

BioMarin Pharmaceutical has agreed…

August 18th, 2026|FierceBiotech|

BioMarin Pharmaceutical has agreed to buy Alesta Therapeutics for $275 million upfront, positioning the biopharma to challenge AstraZeneca for a rare bone disease market.

Amylyx Pharmaceuticals’ $35…

August 17th, 2026|FierceBiotech|

Amylyx Pharmaceuticals’ $35 million bet on the GLP-1 receptor antagonist avexitide appears to have paid off, with the molecule cutting the number of dangerous blood sugar crashes by more than half in patients with a

Regeneron has hit the brakes on…

August 17th, 2026|FierceBiotech|

Regeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.

The Massachusetts research site…

August 17th, 2026|FierceBiotech|

The Massachusetts research site for Merck KGaA’s North American division, EMD Serono, has decided to hand pink slips to 20 staffers, Fierce has learned.

Slate Medicines is hurtling toward…

August 17th, 2026|FierceBiotech|

Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after exiting stealth and ahead of the publication of clinical data on its lead candidate.